Literature DB >> 7616409

Characterization of a recombinant human dopamine transporter in multiple cell lines.

A J Eshleman1, R L Neve, A Janowsky, K A Neve.   

Abstract

A 3.5-kilobase cDNA encoding the dopamine transporter was isolated from a human substantia nigra cDNA library. Sequence analysis of the coding region of the transporter identified two nucleotide differences between the cDNA and published human dopamine transporter sequences. One of the substitutions changed an amino acid conserved among previously cloned dopamine (DA) and norepinephrine transporters, Arg-344, to a methionine. C6 glioma cells or COS-7 cells transfected with the cDNA (C6-hDAT and Cos7-hDAT cells) accumulated [3H]DA with high affinity (Km = 1.2 and 1.5 microM, respectively), and DA uptake inhibitors had similar potencies in both cell lines. [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane ([3H]CFT) bound to membranes prepared from both cell lines with high affinity (Kd = 2-6 nM), although some experiments with C6-hDAT cell membranes indicated the presence of a second class of binding sites with lower affinity for the radioligand. Using the high-affinity Kd value for [3H]CFT binding determined in Cos7-hDAT cells to calculate Ki values, drug affinity for inhibition was highly correlated (r = .92) with affinity for inhibition of [3H]DA uptake, although transporter substrates were significantly more potent inhibitors of uptake than of [3H]CFT binding. The binding of [3H]1-[2-diphenylmethoxy]ethyl-4-(3-phenylpropyl)-piperazine ([3H]GBR-12935) to C6-hDAT cells could not be characterized due to high binding to untransfected C6 cells, but on Cos7-hDAT cells the radioligand labeled a single population of binding sites (Kd = 1 nM). Inhibition of [3H]GBR-12935 binding by drugs correlated highly with inhibition of either [3H]CFT binding (r = .98) or of [3H]DA uptake (r = .95).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7616409

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.

Authors:  Piotr Popik; Martyna Krawczyk; Krystyna Golembiowska; Gabriel Nowak; Aaron Janowsky; Phil Skolnick; Arnold Lippa; Anthony S Basile
Journal:  Cell Mol Neurobiol       Date:  2006-04-25       Impact factor: 5.046

2.  Melittin initiates dopamine transporter internalization and recycling in transfected HEK-293 cells.

Authors:  Dove J Keith; Katherine Wolfrum; Amy J Eshleman; Aaron Janowsky
Journal:  Eur J Pharmacol       Date:  2012-06-05       Impact factor: 4.432

3.  Drosophila Dopamine2-like receptors function as autoreceptors.

Authors:  Trisha L Vickrey; B Jill Venton
Journal:  ACS Chem Neurosci       Date:  2011-12-21       Impact factor: 4.418

4.  Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.

Authors:  John R Cashman; Troy Voelker; Han-Ting Zhang; James M O'Donnell
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

5.  Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in cells expressing the cloned human dopamine transporter.

Authors:  M E Reith; C Xu; L Zhang; L L Coffey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

6.  Novel C-1 substituted cocaine analogs unlike cocaine or benztropine.

Authors:  Maarten E A Reith; Solav Ali; Audrey Hashim; Imran S Sheikh; Naresh Theddu; Narendra V Gaddiraju; Suneet Mehrotra; Kyle C Schmitt; Thomas F Murray; Henry Sershen; Ellen M Unterwald; Franklin A Davis
Journal:  J Pharmacol Exp Ther       Date:  2012-08-15       Impact factor: 4.030

Review 7.  Model systems for analysis of dopamine transporter function and regulation.

Authors:  Moriah J Hovde; Garret H Larson; Roxanne A Vaughan; James D Foster
Journal:  Neurochem Int       Date:  2018-09-01       Impact factor: 3.921

8.  Melittin stimulates fatty acid release through non-phospholipase-mediated mechanisms and interacts with the dopamine transporter and other membrane-spanning proteins.

Authors:  Dove J Keith; Amy J Eshleman; Aaron Janowsky
Journal:  Eur J Pharmacol       Date:  2010-10-20       Impact factor: 4.432

9.  Role of tyrosine phosphorylation in the antioxidant effects of the p75 neurotrophin receptor.

Authors:  Tong Zhang; Zhiping Mi; Nina F Schor
Journal:  Oxid Med Cell Longev       Date:  2009 Sep-Oct       Impact factor: 6.543

Review 10.  PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter.

Authors:  Patrick Emond; Denis Guilloteau; Sylvie Chalon
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.